CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...
24 Provinces Form Alliances for Volume-Based Procurement of Medical Consumables
The Henan provincial alliance procurement office released a notification indicating that 24 provinces/regions will form...
Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy
Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens...
Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the...
Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform
Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an...
GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development
China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised...
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
SciClone’s Danyelza Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...
Shaanxi Panlong Pharma Partners with Porton Pharma Solutions for Drug Development
China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) announced a technology commission (development) agreement...
Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics
A new bar was set for the most valuable out-license deal struck by a China-based...
Qihui Biopharmaceuticals Raises Series A Funding for Microbubbles Technology
Beijing Qihui Biopharmaceuticals Co., Ltd reportedly raised “tens of millions” of renminbi in a Series...
Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...
Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing
Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of...
Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments
China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to...
NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions
The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the...
MaxHealth Biotechnology Completes Series B+ Financing Round
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...